Low CADM2 expression predicts high recurrence risk of hepatocellular carcinoma patients after hepatectomy

Journal of Cancer Research and Clinical Oncology

Volumn 140, Issue 1, 2014, Pages 109-116

  Yang, Sen ^a   Yan, Hong Li ^a   Tao, Qi Fei ^a   Yuan, Sheng Xian ^a   Tang, Guan Nan ^a   Yang, Yuan ^a   Wang, Li Li ^a   Zhang, Yi Liang ^a   Sun, Shu Han ^a   Zhou, Wei Ping ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

CADM2; Clinical significance; Immunohistochemistry; Liver neoplasms; Relapse

Indexed keywords

ALPHA FETOPROTEIN; CELL ADHESION MOLECULE; CELL ADHESION MOLECULE 2; HEPATITIS B SURFACE ANTIGEN; MESSENGER RNA; UNCLASSIFIED DRUG;

ADULT; ALPHA FETOPROTEIN BLOOD LEVEL; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER TISSUE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; FROZEN SECTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER; LIVER CELL CARCINOMA; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; TISSUE MICROARRAY; TUMOR DIFFERENTIATION; TUMOR INVASION; TUMOR VOLUME; YOUNG ADULT;

EID: 84892676906     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-013-1536-8     Document Type: Article

References (28)

1. Chang G, Xu S, Dhir R, et al. (2010) Hypoexpression and epigenetic regulation of candidate tumor suppressor gene CADM-2 in human prostate cancer. Clin Cancer Res 16:5390-5401. doi: 10.1158/1078-0432.ccr-10-1461
2. Edmondson HA, Steiner PE (1954) Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer 7:462-503
3. El-Serag HB, Rudolph KL (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132:2557-2576. doi: 10.1053/j.gastro.2007.04.061 (Pubitemid 46890874)
4. Faraji F, Pang Y, Walker RC, et al. (2012) Cadm1 is a metastasis susceptibility gene that suppresses metastasis by modifying tumor interaction with the cell-mediated immunity. PLoS Genet 8:e1002926. doi: 10.1371/journal.pgen.1002926
5. Ferlay J, Shin HR, Bray F, et al. (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893-2917. doi: 10.1002/ijc.25516
6. Fong Y, Sun RL, Jarnagin W, et al. (1999) An analysis of 412 cases of hepatocellular carcinoma at a Western center. Ann Surg 229:790-799 (discussion 799-800) (Pubitemid 30191728)
7. Fukuhara H, Kuramochi M, Fukami T, et al. (2002) Promoter methylation of TSLC1 and tumor suppression by its gene product in human prostate cancer. Jpn J Cancer Res 93:605-609 (Pubitemid 34846267)
8. Grazi GL, Ercolani G, Pierangeli F, et al. (2001) Improved results of liver resection for hepatocellular carcinoma on cirrhosis give the procedure added value. Ann Surg 234:71-78 (Pubitemid 32619337)
9. Hoshida Y, Villanueva A, Kobayashi M, et al. (2008) Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 359:1995-2004. doi: 10.1056/NEJMoa0804525
10. Hu J, Xu Y, Shen ZZ, et al. (2009) High expressions of vascular endothelial growth factor and platelet-derived endothelial cell growth factor predict poor prognosis in alpha-fetoprotein-negative hepatocellular carcinoma patients after curative resection. J Cancer Res Clin Oncol 135:1359-1367. doi: 10.1007/s00432-009-0577-5
11. Huang G, Yang Y, Shen F, et al. (2013) Early viral suppression predicts good postoperative survivals in patients with hepatocellular carcinoma with a high baseline HBV-DNA load. Ann Surg Oncol 20:1482-1490. doi: 10.1245/s10434-012-2803-7
12. Imamura H, Matsuyama Y, Tanaka E, et al. (2003) Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 38:200-207 (Pubitemid 36169630)
13. Ito T, Shimada Y, Hashimoto Y, et al. (2003) Involvement of TSLC1 in progression of esophageal squamous cell carcinoma. Cancer Res 63:6320-6326 (Pubitemid 37255179)
14. Ju MJ, Qiu SJ, Gao Q, et al. (2009) Combination of peritumoral mast cells and T-regulatory cells predicts prognosis of hepatocellular carcinoma. Cancer Sci 100:1267-1274. doi: 10.1111/j.1349-7006.2009.01182.x
15. Kuramochi M, Fukuhara H, Nobukuni T, et al. (2001) TSLC1 is a tumor-suppressor gene in human non-small-cell lung cancer. Nat Genet 27:427-430. doi: 10.1038/86934 (Pubitemid 32268425)
16. Li D, Mallory T, Satomura S (2001) AFP-L3: a new generation of tumor marker for hepatocellular carcinoma. Clin Chim Acta 313:15-19 (Pubitemid 33016686)
17. Llovet JM, Bru C, Bruix J (1999) Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19:329-338. doi: 10.1055/s-2007-1007122
18. Mann CD, Neal CP, Garcea G, et al. (2007) Prognostic molecular markers in hepatocellular carcinoma: a systematic review. Eur J Cancer 43:979-992. doi: 10.1016/j.ejca.2007.01.004 (Pubitemid 46483030)
19. Murakami Y (2005) Involvement of a cell adhesion molecule, TSLC1/IGSF4, in human oncogenesis. Cancer Sci 96:543-552. doi: 10.1111/j.1349-7006.2005. 00089.x (Pubitemid 41488417)
20. Nagata M, Sakurai-Yageta M, Yamada D, et al. (2012) Aberrations of a cell adhesion molecule CADM4 in renal clear cell carcinoma. Int J Cancer 130:1329-1337. doi: 10.1002/ijc.26160
21. Raveh S, Gavert N, Spiegel I, et al. (2009) The cell adhesion nectin-like molecules (Necl) 1 and 4 suppress the growth and tumorigenic ability of colon cancer cells. J Cell Biochem 108:326-336. doi: 10.1002/jcb.22258
22. Shiraki K, Takase K, Tameda Y, et al. (1995) A clinical study of lectin-reactive alpha-fetoprotein as an early indicator of hepatocellular carcinoma in the follow-up of cirrhotic patients. Hepatology 22:802-807
23. Takahashi Y, Iwai M, Kawai T, et al. (2012) Aberrant expression of tumor suppressors CADM1 and 4.1B in invasive lesions of primary breast cancer. Breast Cancer 19:242-252. doi: 10.1007/s12282-011-0272-7
24. Takai Y, Irie K, Shimizu K, et al. (2003) Nectins and nectin-like molecules: roles in cell adhesion, migration, and polarization. Cancer Sci 94:655-667 (Pubitemid 37160921)
25. Takayama T (2011) Surgical treatment for hepatocellular carcinoma. Jpn J Clin Oncol 41:447-454. doi: 10.1093/jjco/hyr016
26. Tsukuma H, Hiyama T, Tanaka S, et al. (1993) Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 328:1797-1801. doi: 10.1056/nejm199306243282501 (Pubitemid 23174709)
27. Williams YN, Masuda M, Sakurai-Yageta M, et al. (2006) Cell adhesion and prostate tumor-suppressor activity of TSLL2/IGSF4C, an immunoglobulin superfamily molecule homologous to TSLC1/IGSF4. Oncogene 25:1446-1453. doi: 10.1038/sj.onc.1209192 (Pubitemid 43361930)
28. Wu CY, Chen YJ, Ho HJ, et al. (2012) Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection. JAMA 308:1906-1914